People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Biotechnology, Pharmaceuticals, Other Health Care, Agriculture
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | — | Biotechnology | Growth/Late | $527.8M | $5.7B | 2016 |
| Outlook Therapeutics, Inc. | — | Biotechnology | Series C | $213.0M | $231.3M | 2015 |
| Vero Biotech Inc. | — | Pharmaceuticals | Series B | $82.1M | $525.0M | 2021 |
| Aldeyra Therapeutics, Inc. | — | Biotechnology | Series A | $24.6M | $361.5M | 2012 |
| Tyrogenex, Inc. | — | Biotechnology | Series A | $14.6M | $19.7M | 2016 |
| Asmacure, Inc. | — | Other Health Care | Series A | $7.9M | $80.8M | 2010 |
| Rx Green Solutions LLC | — | Agriculture | Series A | $5.7M | $46.2M | 2013 |
Todd Brady at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Todd Brady on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd C. Brady | 2 | 3 |
| Asish Xavier | 1 | 18 |
| Michael Martin | 1 | 11 |
| John Henderson | 1 | 8 |
| John Brady | 1 | 7 |
| Troy Wilson | 1 | 7 |
| Michael Webb | 1 | 6 |
| James O'Brien | 1 | 5 |
| Jesse I. Treu | 1 | 5 |
| Roderick Wong | 1 | 4 |
| Gary Phillips | 1 | 4 |
| Ben Bronstein | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| Gerald Cagle | 1 | 4 |
| Steven Shulman | 1 | 3 |
| MARTIN GODBOUT | 1 | 3 |
| Martin Driscoll | 1 | 3 |
| SHERIDAN G. SNYDER | 1 | 3 |
| George Matelich | 1 | 3 |
| Pankaj Mohan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.